Review



blood vessels marker cd31  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 98

    Structured Review

    R&D Systems blood vessels marker cd31
    Intranasal tPA administration attenuates pial and neocortical CAA in aged Tg2576 mice. A, In vivo two‐photon excited fluorescent images illustrating methoxy‐XO4 + amyloid deposits (magenta) around somatosensory cortex blood vessels (green) identified by retroorbital injection of 70 kDa Texas Red dextran. Methoxy‐XO4 + Aβ deposits are reduced in intranasal tPA‐treated Tg2576 compared to vehicle‐treated Tg2576 mice. B, CAA burden (% thioflavin‐S + area) in cortical sections labeled with thioflavin‐S and the blood vessel marker <t>CD31</t> is reduced in intranasal tPA‐treated Tg2576 compared to vehicle‐treated Tg2576 mice, but amyloid plaque burden (% thioflavin‐S + plaque area) was comparable between the two groups. In (A) and (B), arrows indicate CAA and arrowheads plaques. N = 5/group; unpaired t test; scale bars, 100 μm in (A) and 200 μm in (B); data presented as mean ± standard error of the mean. Aβ, amyloid beta; CAA, cerebral amyloid angiopathy; tPA, tissue plasminogen activator; WT, wild type.
    Blood Vessels Marker Cd31, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1248 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/blood+vessel+marker+cd31/Human%2FMouse%2FRat+CD31%2FPECAM-1+Antibody/pmc11247712-77-15-25
    Average 98 stars, based on 1248 article reviews
    blood vessels marker cd31 - by Bioz Stars, 2026-09
    98/100 stars

    Images

    1) Product Images from "tPA supplementation preserves neurovascular and cognitive function in Tg2576 mice"

    Article Title: tPA supplementation preserves neurovascular and cognitive function in Tg2576 mice

    Journal: Alzheimer's & Dementia

    doi: 10.1002/alz.13878

    Intranasal tPA administration attenuates pial and neocortical CAA in aged Tg2576 mice. A, In vivo two‐photon excited fluorescent images illustrating methoxy‐XO4 + amyloid deposits (magenta) around somatosensory cortex blood vessels (green) identified by retroorbital injection of 70 kDa Texas Red dextran. Methoxy‐XO4 + Aβ deposits are reduced in intranasal tPA‐treated Tg2576 compared to vehicle‐treated Tg2576 mice. B, CAA burden (% thioflavin‐S + area) in cortical sections labeled with thioflavin‐S and the blood vessel marker CD31 is reduced in intranasal tPA‐treated Tg2576 compared to vehicle‐treated Tg2576 mice, but amyloid plaque burden (% thioflavin‐S + plaque area) was comparable between the two groups. In (A) and (B), arrows indicate CAA and arrowheads plaques. N = 5/group; unpaired t test; scale bars, 100 μm in (A) and 200 μm in (B); data presented as mean ± standard error of the mean. Aβ, amyloid beta; CAA, cerebral amyloid angiopathy; tPA, tissue plasminogen activator; WT, wild type.
    Figure Legend Snippet: Intranasal tPA administration attenuates pial and neocortical CAA in aged Tg2576 mice. A, In vivo two‐photon excited fluorescent images illustrating methoxy‐XO4 + amyloid deposits (magenta) around somatosensory cortex blood vessels (green) identified by retroorbital injection of 70 kDa Texas Red dextran. Methoxy‐XO4 + Aβ deposits are reduced in intranasal tPA‐treated Tg2576 compared to vehicle‐treated Tg2576 mice. B, CAA burden (% thioflavin‐S + area) in cortical sections labeled with thioflavin‐S and the blood vessel marker CD31 is reduced in intranasal tPA‐treated Tg2576 compared to vehicle‐treated Tg2576 mice, but amyloid plaque burden (% thioflavin‐S + plaque area) was comparable between the two groups. In (A) and (B), arrows indicate CAA and arrowheads plaques. N = 5/group; unpaired t test; scale bars, 100 μm in (A) and 200 μm in (B); data presented as mean ± standard error of the mean. Aβ, amyloid beta; CAA, cerebral amyloid angiopathy; tPA, tissue plasminogen activator; WT, wild type.

    Techniques Used: In Vivo, Injection, Labeling, Marker

    Related Articles

    Staining:

    Article Title: Sensitivity of Multiphase Pseudocontinuous Arterial Spin Labelling (MP pCASL) Magnetic Resonance Imaging for Measuring Brain and Tumour Blood Flow in Mice.
    Article Snippet: .. Sections were stained for the blood vessel marker CD31 (AF3628, R&D systems, Abingdon, UK) according to the method described by Andreou et al. [37]. .. Microvessel density (vessel area fraction) was quanti ed for the core and rim regions of the entire tumour, and also for the contralateral striatum, as the percentage of area covered using the “Positive Pixel Count 2004-08-11” algorithm in Imagescope (Leica Biosystems). e parameters used for perfusion- xed tumour model 10μm sections were moderately stained pixel intensity between 202 and 185 and strongly stained pixel intensity lower than 10. e parameters used for post xed 20 μm autoradiography sections were moderately stained pixel intensity between 180 and 171, and strongly stained pixel intensity lower than 53.

    Article Title: Imaging angiogenesis in an intracerebrally induced model of brain macrometastasis using α v β 3 ‐targeted iron oxide microparticles
    Article Snippet: .. Brain tissue sections were stained for blood vessel marker CD31 (AF3628, R&D Systems), VCAM‐1 (1510‐14, Southern Biotech), and the macrophage/microglia marker Iba‐1 (ab5076, Abcam, Cambridge, UK), as described previously., , Secondary antibodies used were biotinylated horse anti‐goat IgG (BA‐9500, Vector Laboratories, Peterborough, UK) and biotinylated goat anti‐rat IgG (BA‐9401, Vector Laboratories). .. Sections were also stained for the angiogenic marker integrin α v β 3 (ab78289, Abcam) using Mouse on Mouse Basic Kit (BMK‐2202, Vector Laboratories) in accordance with the protocol described by the manufacturer.

    Article Title: Imaging angiogenesis in an intracerebrally induced model of brain macrometastasis using α v β 3 -targeted iron oxide microparticles
    Article Snippet: .. Brain tissue sections were stained for blood vessel marker CD31 (AF3628, R&D Systems, Abingdon, UK), VCAM-1 (1510-14, Southern Biotech, Birmingham, USA) and the macrophage/microglia marker Iba-1 (ab5076, Abcam, Cambridge, UK), as described previously – . .. Secondary antibodies used were biotinylated horse anti-goat IgG (BA-9500, Vector Laboratories, Peterborough, UK), and biotinylated goat anti-rat IgG (BA-9401, Vector Laboratories, Peterborough, UK).

    Article Title: Imaging angiogenesis in an intracerebrally induced model of brain macrometastasis using α v β 3 -targeted iron oxide microparticles.
    Article Snippet: .. Brain tissue sections were stained for blood vessel marker CD31 (AF3628, R&D Systems), VCAM-1 (1510-14, Southern Biotech), and the macrophage/microglia marker Iba-1 (ab5076, Abcam, Cambridge, UK), as described previously.45–47 Secondary antibodies used were biotinylated horse anti-goat IgG (BA-9500, Vector Laboratories, Peterborough, UK) and biotinylated goat anti-rat IgG (BA-9401, Vector Laboratories). .. Sections were also stained for the angiogenic marker integrin αvβ3 (ab78289, Abcam) using Mouse on Mouse Basic Kit (BMK-2202, Vector Laboratories) in accordance with the protocol described by the manufacturer.

    Marker:

    Article Title: Sensitivity of Multiphase Pseudocontinuous Arterial Spin Labelling (MP pCASL) Magnetic Resonance Imaging for Measuring Brain and Tumour Blood Flow in Mice.
    Article Snippet: .. Sections were stained for the blood vessel marker CD31 (AF3628, R&D systems, Abingdon, UK) according to the method described by Andreou et al. [37]. .. Microvessel density (vessel area fraction) was quanti ed for the core and rim regions of the entire tumour, and also for the contralateral striatum, as the percentage of area covered using the “Positive Pixel Count 2004-08-11” algorithm in Imagescope (Leica Biosystems). e parameters used for perfusion- xed tumour model 10μm sections were moderately stained pixel intensity between 202 and 185 and strongly stained pixel intensity lower than 10. e parameters used for post xed 20 μm autoradiography sections were moderately stained pixel intensity between 180 and 171, and strongly stained pixel intensity lower than 53.

    Article Title: Imaging angiogenesis in an intracerebrally induced model of brain macrometastasis using α v β 3 ‐targeted iron oxide microparticles
    Article Snippet: .. Brain tissue sections were stained for blood vessel marker CD31 (AF3628, R&D Systems), VCAM‐1 (1510‐14, Southern Biotech), and the macrophage/microglia marker Iba‐1 (ab5076, Abcam, Cambridge, UK), as described previously., , Secondary antibodies used were biotinylated horse anti‐goat IgG (BA‐9500, Vector Laboratories, Peterborough, UK) and biotinylated goat anti‐rat IgG (BA‐9401, Vector Laboratories). .. Sections were also stained for the angiogenic marker integrin α v β 3 (ab78289, Abcam) using Mouse on Mouse Basic Kit (BMK‐2202, Vector Laboratories) in accordance with the protocol described by the manufacturer.

    Article Title: Imaging angiogenesis in an intracerebrally induced model of brain macrometastasis using α v β 3 -targeted iron oxide microparticles
    Article Snippet: .. Brain tissue sections were stained for blood vessel marker CD31 (AF3628, R&D Systems, Abingdon, UK), VCAM-1 (1510-14, Southern Biotech, Birmingham, USA) and the macrophage/microglia marker Iba-1 (ab5076, Abcam, Cambridge, UK), as described previously – . .. Secondary antibodies used were biotinylated horse anti-goat IgG (BA-9500, Vector Laboratories, Peterborough, UK), and biotinylated goat anti-rat IgG (BA-9401, Vector Laboratories, Peterborough, UK).

    Article Title: Imaging angiogenesis in an intracerebrally induced model of brain macrometastasis using α v β 3 -targeted iron oxide microparticles.
    Article Snippet: .. Brain tissue sections were stained for blood vessel marker CD31 (AF3628, R&D Systems), VCAM-1 (1510-14, Southern Biotech), and the macrophage/microglia marker Iba-1 (ab5076, Abcam, Cambridge, UK), as described previously.45–47 Secondary antibodies used were biotinylated horse anti-goat IgG (BA-9500, Vector Laboratories, Peterborough, UK) and biotinylated goat anti-rat IgG (BA-9401, Vector Laboratories). .. Sections were also stained for the angiogenic marker integrin αvβ3 (ab78289, Abcam) using Mouse on Mouse Basic Kit (BMK-2202, Vector Laboratories) in accordance with the protocol described by the manufacturer.



    Similar Products

    98
    R&D Systems blood vessels marker cd31
    Intranasal tPA administration attenuates pial and neocortical CAA in aged Tg2576 mice. A, In vivo two‐photon excited fluorescent images illustrating methoxy‐XO4 + amyloid deposits (magenta) around somatosensory cortex blood vessels (green) identified by retroorbital injection of 70 kDa Texas Red dextran. Methoxy‐XO4 + Aβ deposits are reduced in intranasal tPA‐treated Tg2576 compared to vehicle‐treated Tg2576 mice. B, CAA burden (% thioflavin‐S + area) in cortical sections labeled with thioflavin‐S and the blood vessel marker <t>CD31</t> is reduced in intranasal tPA‐treated Tg2576 compared to vehicle‐treated Tg2576 mice, but amyloid plaque burden (% thioflavin‐S + plaque area) was comparable between the two groups. In (A) and (B), arrows indicate CAA and arrowheads plaques. N = 5/group; unpaired t test; scale bars, 100 μm in (A) and 200 μm in (B); data presented as mean ± standard error of the mean. Aβ, amyloid beta; CAA, cerebral amyloid angiopathy; tPA, tissue plasminogen activator; WT, wild type.
    Blood Vessels Marker Cd31, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/blood+vessel+marker+cd31/Human%2FMouse%2FRat+CD31%2FPECAM-1+Antibody/pmc11247712-77-15-25
    Average 98 stars, based on 1 article reviews
    blood vessels marker cd31 - by Bioz Stars, 2026-09
    98/100 stars
      Buy from Supplier

    98
    R&D Systems blood vessel marker cd31
    (A) Quantitation of <t>CD31</t> total stained area as a percentage of tumour area in the tumour (blue circles) and the contralateral striatum (red squares), plotted against time with 95% confidence intervals. A significant increase in blood vessels in the tumour is evident after Day 12 (linear regression sum‐of‐squares F‐test, p < 0.05; Spearman's r, tumour regression: 0.75, p < 0.0001; contralateral striatum regression: 0.74, p < 0.0001). (B) Comparison of microvessel density (CD31 positive vessels) in the tumour (blue circles) and the contralateral striatum (red squares), plotted against time with 95% confidence intervals. A significant increase in blood vessels in the tumour is evident after Day 13 (linear regression sum‐of‐squares F‐test, p < 0.05; Spearman's r, tumour regression: 0.56, p < 0.01; contralateral striatum: 0.51, p < 0.05). (C) Quantitation of total α v β 3 ‐stained area as a percentage of tumour area across the timecourse. (D) Quantitation of α v β 3 positive vessels across the timecourse. (E) Number of α v β 3 positive vessels correlated positively with tumour size (Pearson's coefficient p < 0.0001, R 2 = 0.88). (F) Number of α v β 3 positive vessels correlated positively with CD31 microvessel density (Pearson's coefficient, p < 0.001, R 2 = 0.46). In all cases, PBS control ( n = 3), Days 7 ( n = 4), 14 ( n = 6), 21 ( n = 3), 28 ( n = 4), and 35 ( n = 4). Data for these figures had a lognormal distribution, and no outliers were found to be present (ROUT test). Bars represent mean ± standard deviation; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. PBS, phosphate‐buffered saline.
    Blood Vessel Marker Cd31, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/blood+vessel+marker+cd31/Human%2FMouse%2FRat+CD31%2FPECAM-1+Antibody/pmc10909432-94-6-11
    Average 98 stars, based on 1 article reviews
    blood vessel marker cd31 - by Bioz Stars, 2026-09
    98/100 stars
      Buy from Supplier

    96
    R&D Systems blood vessel endothelial marker
    (A) Quantitation of <t>CD31</t> total stained area as a percentage of tumour area in the tumour (blue circles) and the contralateral striatum (red squares), plotted against time with 95% confidence intervals. A significant increase in blood vessels in the tumour is evident after Day 12 (linear regression sum‐of‐squares F‐test, p < 0.05; Spearman's r, tumour regression: 0.75, p < 0.0001; contralateral striatum regression: 0.74, p < 0.0001). (B) Comparison of microvessel density (CD31 positive vessels) in the tumour (blue circles) and the contralateral striatum (red squares), plotted against time with 95% confidence intervals. A significant increase in blood vessels in the tumour is evident after Day 13 (linear regression sum‐of‐squares F‐test, p < 0.05; Spearman's r, tumour regression: 0.56, p < 0.01; contralateral striatum: 0.51, p < 0.05). (C) Quantitation of total α v β 3 ‐stained area as a percentage of tumour area across the timecourse. (D) Quantitation of α v β 3 positive vessels across the timecourse. (E) Number of α v β 3 positive vessels correlated positively with tumour size (Pearson's coefficient p < 0.0001, R 2 = 0.88). (F) Number of α v β 3 positive vessels correlated positively with CD31 microvessel density (Pearson's coefficient, p < 0.001, R 2 = 0.46). In all cases, PBS control ( n = 3), Days 7 ( n = 4), 14 ( n = 6), 21 ( n = 3), 28 ( n = 4), and 35 ( n = 4). Data for these figures had a lognormal distribution, and no outliers were found to be present (ROUT test). Bars represent mean ± standard deviation; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. PBS, phosphate‐buffered saline.
    Blood Vessel Endothelial Marker, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/blood+vessel+marker+cd31/Human%2FMouse%2FRat+CD31%2FPECAM-1+Antibody/pm35379347-198-73-78
    Average 96 stars, based on 1 article reviews
    blood vessel endothelial marker - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    90
    Servicebio Inc mouse monoclonal antibody against the specific cell surface marker for new blood vessels cd31
    (A) Quantitation of <t>CD31</t> total stained area as a percentage of tumour area in the tumour (blue circles) and the contralateral striatum (red squares), plotted against time with 95% confidence intervals. A significant increase in blood vessels in the tumour is evident after Day 12 (linear regression sum‐of‐squares F‐test, p < 0.05; Spearman's r, tumour regression: 0.75, p < 0.0001; contralateral striatum regression: 0.74, p < 0.0001). (B) Comparison of microvessel density (CD31 positive vessels) in the tumour (blue circles) and the contralateral striatum (red squares), plotted against time with 95% confidence intervals. A significant increase in blood vessels in the tumour is evident after Day 13 (linear regression sum‐of‐squares F‐test, p < 0.05; Spearman's r, tumour regression: 0.56, p < 0.01; contralateral striatum: 0.51, p < 0.05). (C) Quantitation of total α v β 3 ‐stained area as a percentage of tumour area across the timecourse. (D) Quantitation of α v β 3 positive vessels across the timecourse. (E) Number of α v β 3 positive vessels correlated positively with tumour size (Pearson's coefficient p < 0.0001, R 2 = 0.88). (F) Number of α v β 3 positive vessels correlated positively with CD31 microvessel density (Pearson's coefficient, p < 0.001, R 2 = 0.46). In all cases, PBS control ( n = 3), Days 7 ( n = 4), 14 ( n = 6), 21 ( n = 3), 28 ( n = 4), and 35 ( n = 4). Data for these figures had a lognormal distribution, and no outliers were found to be present (ROUT test). Bars represent mean ± standard deviation; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. PBS, phosphate‐buffered saline.
    Mouse Monoclonal Antibody Against The Specific Cell Surface Marker For New Blood Vessels Cd31, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/blood+vessel+marker+cd31/cd31+antibody/pm33737175-102-12-16
    Average 90 stars, based on 1 article reviews
    mouse monoclonal antibody against the specific cell surface marker for new blood vessels cd31 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    Image Search Results


    Intranasal tPA administration attenuates pial and neocortical CAA in aged Tg2576 mice. A, In vivo two‐photon excited fluorescent images illustrating methoxy‐XO4 + amyloid deposits (magenta) around somatosensory cortex blood vessels (green) identified by retroorbital injection of 70 kDa Texas Red dextran. Methoxy‐XO4 + Aβ deposits are reduced in intranasal tPA‐treated Tg2576 compared to vehicle‐treated Tg2576 mice. B, CAA burden (% thioflavin‐S + area) in cortical sections labeled with thioflavin‐S and the blood vessel marker CD31 is reduced in intranasal tPA‐treated Tg2576 compared to vehicle‐treated Tg2576 mice, but amyloid plaque burden (% thioflavin‐S + plaque area) was comparable between the two groups. In (A) and (B), arrows indicate CAA and arrowheads plaques. N = 5/group; unpaired t test; scale bars, 100 μm in (A) and 200 μm in (B); data presented as mean ± standard error of the mean. Aβ, amyloid beta; CAA, cerebral amyloid angiopathy; tPA, tissue plasminogen activator; WT, wild type.

    Journal: Alzheimer's & Dementia

    Article Title: tPA supplementation preserves neurovascular and cognitive function in Tg2576 mice

    doi: 10.1002/alz.13878

    Figure Lengend Snippet: Intranasal tPA administration attenuates pial and neocortical CAA in aged Tg2576 mice. A, In vivo two‐photon excited fluorescent images illustrating methoxy‐XO4 + amyloid deposits (magenta) around somatosensory cortex blood vessels (green) identified by retroorbital injection of 70 kDa Texas Red dextran. Methoxy‐XO4 + Aβ deposits are reduced in intranasal tPA‐treated Tg2576 compared to vehicle‐treated Tg2576 mice. B, CAA burden (% thioflavin‐S + area) in cortical sections labeled with thioflavin‐S and the blood vessel marker CD31 is reduced in intranasal tPA‐treated Tg2576 compared to vehicle‐treated Tg2576 mice, but amyloid plaque burden (% thioflavin‐S + plaque area) was comparable between the two groups. In (A) and (B), arrows indicate CAA and arrowheads plaques. N = 5/group; unpaired t test; scale bars, 100 μm in (A) and 200 μm in (B); data presented as mean ± standard error of the mean. Aβ, amyloid beta; CAA, cerebral amyloid angiopathy; tPA, tissue plasminogen activator; WT, wild type.

    Article Snippet: To quantify CAA and amyloid plaque burden, , , coronal sections were stained with the blood vessels marker CD31 (goat polyclonal, 1:150, Catalog # AF3628, R&D Systems) followed by thioflavin‐S (0.5%), mounted on slides, and imaged with a confocal microscope (Leica SP8).

    Techniques: In Vivo, Injection, Labeling, Marker

    (A) Quantitation of CD31 total stained area as a percentage of tumour area in the tumour (blue circles) and the contralateral striatum (red squares), plotted against time with 95% confidence intervals. A significant increase in blood vessels in the tumour is evident after Day 12 (linear regression sum‐of‐squares F‐test, p < 0.05; Spearman's r, tumour regression: 0.75, p < 0.0001; contralateral striatum regression: 0.74, p < 0.0001). (B) Comparison of microvessel density (CD31 positive vessels) in the tumour (blue circles) and the contralateral striatum (red squares), plotted against time with 95% confidence intervals. A significant increase in blood vessels in the tumour is evident after Day 13 (linear regression sum‐of‐squares F‐test, p < 0.05; Spearman's r, tumour regression: 0.56, p < 0.01; contralateral striatum: 0.51, p < 0.05). (C) Quantitation of total α v β 3 ‐stained area as a percentage of tumour area across the timecourse. (D) Quantitation of α v β 3 positive vessels across the timecourse. (E) Number of α v β 3 positive vessels correlated positively with tumour size (Pearson's coefficient p < 0.0001, R 2 = 0.88). (F) Number of α v β 3 positive vessels correlated positively with CD31 microvessel density (Pearson's coefficient, p < 0.001, R 2 = 0.46). In all cases, PBS control ( n = 3), Days 7 ( n = 4), 14 ( n = 6), 21 ( n = 3), 28 ( n = 4), and 35 ( n = 4). Data for these figures had a lognormal distribution, and no outliers were found to be present (ROUT test). Bars represent mean ± standard deviation; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. PBS, phosphate‐buffered saline.

    Journal: Nmr in Biomedicine

    Article Title: Imaging angiogenesis in an intracerebrally induced model of brain macrometastasis using α v β 3 ‐targeted iron oxide microparticles

    doi: 10.1002/nbm.4948

    Figure Lengend Snippet: (A) Quantitation of CD31 total stained area as a percentage of tumour area in the tumour (blue circles) and the contralateral striatum (red squares), plotted against time with 95% confidence intervals. A significant increase in blood vessels in the tumour is evident after Day 12 (linear regression sum‐of‐squares F‐test, p < 0.05; Spearman's r, tumour regression: 0.75, p < 0.0001; contralateral striatum regression: 0.74, p < 0.0001). (B) Comparison of microvessel density (CD31 positive vessels) in the tumour (blue circles) and the contralateral striatum (red squares), plotted against time with 95% confidence intervals. A significant increase in blood vessels in the tumour is evident after Day 13 (linear regression sum‐of‐squares F‐test, p < 0.05; Spearman's r, tumour regression: 0.56, p < 0.01; contralateral striatum: 0.51, p < 0.05). (C) Quantitation of total α v β 3 ‐stained area as a percentage of tumour area across the timecourse. (D) Quantitation of α v β 3 positive vessels across the timecourse. (E) Number of α v β 3 positive vessels correlated positively with tumour size (Pearson's coefficient p < 0.0001, R 2 = 0.88). (F) Number of α v β 3 positive vessels correlated positively with CD31 microvessel density (Pearson's coefficient, p < 0.001, R 2 = 0.46). In all cases, PBS control ( n = 3), Days 7 ( n = 4), 14 ( n = 6), 21 ( n = 3), 28 ( n = 4), and 35 ( n = 4). Data for these figures had a lognormal distribution, and no outliers were found to be present (ROUT test). Bars represent mean ± standard deviation; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. PBS, phosphate‐buffered saline.

    Article Snippet: Brain tissue sections were stained for blood vessel marker CD31 (AF3628, R&D Systems), VCAM‐1 (1510‐14, Southern Biotech), and the macrophage/microglia marker Iba‐1 (ab5076, Abcam, Cambridge, UK), as described previously., , Secondary antibodies used were biotinylated horse anti‐goat IgG (BA‐9500, Vector Laboratories, Peterborough, UK) and biotinylated goat anti‐rat IgG (BA‐9401, Vector Laboratories).

    Techniques: Quantitation Assay, Staining, Comparison, Control, Standard Deviation, Saline

    Aggregations of iron in 4T1‐GFP tumour tissue. (A) Representative section of gadolinium‐enhancing tumour stained for Perls' Prussian blue (iron, blue) and counterstained with nuclear fast red. Black arrowheads indicate examples of single MPIO associated with the vascular endothelium, and red arrowheads indicate examples of iron aggregations. (B–C) Correlations between iron aggregations and tumour size in mice injected with either (B) RGD‐MPIO or (C) Control RDG‐MPIO. Linear regression analysis showed a positive correlation between number of aggregations and tumour size ( R 2 = 0.64, *** p < 0.001) in mice injected with RGD‐MPIO, but not control RDG‐MPIO, although a similar trend was evident; 95% confidence intervals are shown. (D–F) Consecutive sections stained for (D) Iba‐1 (macrophages and microglia, brown staining), (E) Prussian blue (iron), and (F) CD31 (blood vessels, brown staining) in a Day 35 mouse injected with RGD‐MPIO. The red arrow indicates a larger iron aggregation in a similar location to macrophage staining (D; Iba‐1), while the black arrow indicates single MPIO distant from macrophage staining, but close alignment with a blood vessel (F; CD31). (G–H) Double staining of 4T1‐GFP tumour tissue sections, from a mouse injected with RGD‐MPIO at the Day 35 timepoint, for Prussian blue (iron) and macrophages/microglia (Iba‐1, brown staining), indicate colocalisation of iron within macrophages/microglia (red arrows). Sections counterstained with nuclear fast red. (I) Double staining for Prussian Blue and CD31 revealed single MPIO (black arrow) bound to blood vessels (brown stained) in mice injected with RGD‐MPIO; representative image from Day 21 shown. (J) In the gadolinium‐enhancing 4T1‐GFP tumours, single endothelium‐bound MPIO are observed more often in mice injected with RGD‐MPIO ( n = 10) than control RDG‐MPIO ( n = 3, t ‐test, ** p < 0.01). (K) Histogram showing the cumulative frequency of the measured distance between the centre of the iron‐laden macrophages and the centre of the blood vessel lumen, indicating their close association with blood vessels. Scale bar = 25 μm in (A) and 10 μm in (D–I). MPIO, microparticles of iron oxide; RDG, Arg‐Asp‐Gly peptide, scrambled control; RGD, Arg‐Gly‐Asp peptide, targeting integrin α v β 3 .

    Journal: Nmr in Biomedicine

    Article Title: Imaging angiogenesis in an intracerebrally induced model of brain macrometastasis using α v β 3 ‐targeted iron oxide microparticles

    doi: 10.1002/nbm.4948

    Figure Lengend Snippet: Aggregations of iron in 4T1‐GFP tumour tissue. (A) Representative section of gadolinium‐enhancing tumour stained for Perls' Prussian blue (iron, blue) and counterstained with nuclear fast red. Black arrowheads indicate examples of single MPIO associated with the vascular endothelium, and red arrowheads indicate examples of iron aggregations. (B–C) Correlations between iron aggregations and tumour size in mice injected with either (B) RGD‐MPIO or (C) Control RDG‐MPIO. Linear regression analysis showed a positive correlation between number of aggregations and tumour size ( R 2 = 0.64, *** p < 0.001) in mice injected with RGD‐MPIO, but not control RDG‐MPIO, although a similar trend was evident; 95% confidence intervals are shown. (D–F) Consecutive sections stained for (D) Iba‐1 (macrophages and microglia, brown staining), (E) Prussian blue (iron), and (F) CD31 (blood vessels, brown staining) in a Day 35 mouse injected with RGD‐MPIO. The red arrow indicates a larger iron aggregation in a similar location to macrophage staining (D; Iba‐1), while the black arrow indicates single MPIO distant from macrophage staining, but close alignment with a blood vessel (F; CD31). (G–H) Double staining of 4T1‐GFP tumour tissue sections, from a mouse injected with RGD‐MPIO at the Day 35 timepoint, for Prussian blue (iron) and macrophages/microglia (Iba‐1, brown staining), indicate colocalisation of iron within macrophages/microglia (red arrows). Sections counterstained with nuclear fast red. (I) Double staining for Prussian Blue and CD31 revealed single MPIO (black arrow) bound to blood vessels (brown stained) in mice injected with RGD‐MPIO; representative image from Day 21 shown. (J) In the gadolinium‐enhancing 4T1‐GFP tumours, single endothelium‐bound MPIO are observed more often in mice injected with RGD‐MPIO ( n = 10) than control RDG‐MPIO ( n = 3, t ‐test, ** p < 0.01). (K) Histogram showing the cumulative frequency of the measured distance between the centre of the iron‐laden macrophages and the centre of the blood vessel lumen, indicating their close association with blood vessels. Scale bar = 25 μm in (A) and 10 μm in (D–I). MPIO, microparticles of iron oxide; RDG, Arg‐Asp‐Gly peptide, scrambled control; RGD, Arg‐Gly‐Asp peptide, targeting integrin α v β 3 .

    Article Snippet: Brain tissue sections were stained for blood vessel marker CD31 (AF3628, R&D Systems), VCAM‐1 (1510‐14, Southern Biotech), and the macrophage/microglia marker Iba‐1 (ab5076, Abcam, Cambridge, UK), as described previously., , Secondary antibodies used were biotinylated horse anti‐goat IgG (BA‐9500, Vector Laboratories, Peterborough, UK) and biotinylated goat anti‐rat IgG (BA‐9401, Vector Laboratories).

    Techniques: Staining, Injection, Control, Double Staining